D.C. Circuit: FDA’s Denial Of Abuse-Deterrent Opioid Drug Was Reasonable
WASHINGTON, D.C. — The District of Columbia Circuit U.S. Court of Appeals on May 1 said the Food and Drug Administration’s denial of an application for an abuse-deterrent formulation (ADF) for...To view the full article, register now.
Already a subscriber? Click here to view full article